Description

The Hepatic Fibrosis Test YGA1357 // YGA1361 is a crucial diagnostic tool for the early detection of liver fibrosis, a condition that can significantly impair liver function if left untreated. Early-stage hepatic fibrosis is reversible, making early detection essential for preventing the progression to cirrhosis, which is much harder to treat. This test kit is designed to measure several important biomarkers related to liver health, including PIIINP, CIV, LN, HA, and CG, which provide an accurate representation of liver fibrosis levels.

The Hepatic Fibrosis Test is compatible with Chemiluminescence Immunoassay Analyzers YR06389 and YR06390, ensuring seamless integration into laboratory workflows. By utilizing advanced CLIA (Chemiluminescence Immunoassay) technology, this test offers high sensitivity and accuracy, enabling clinicians to make informed decisions about early intervention and treatment plans. The kit is an invaluable tool in improving the prognosis and quality of life for patients suffering from liver-related diseases.

Market Price

The Hepatic Fibrosis Test YGA1357 // YGA1361 is available at competitive pricing, typically ranging from $86 to $100 per test depending on the packaging (50T/BOX, 100T/BOX, etc.). Laboratories, clinics, and healthcare facilities can obtain volume discounts, making it an affordable solution for high-throughput testing. A tailored quote can be requested through Kalstein Plus to meet specific needs and operational requirements.

Frequently Asked Questions

• What markers are tested in the Hepatic Fibrosis Test YGA1357? The test measures key markers of hepatic fibrosis, including PIIINP, CIV, LN, HA, and CG, which help evaluate the extent of liver damage and fibrosis.

• How is the Hepatic Fibrosis Test performed? The test is compatible with Chemiluminescence Immunoassay Analyzers, and the samples are analyzed using CLIA technology, which offers high sensitivity and accuracy.

• How should the test kit be stored? The test kit should be stored between 2-8°C to maintain its integrity and accuracy.

Advantages and Disadvantages

Advantages:

• Early detection of liver fibrosis, which can significantly improve patient outcomes through timely intervention.
• High accuracy and sensitivity, ensuring reliable results with minimal risk of false negatives.
• Compatible with automated Chemiluminescence Immunoassay Analyzers, increasing lab efficiency and throughput.
• The kit includes a comprehensive set of biomarkers that cover all essential aspects of liver function.

Disadvantages:

• The need for specific storage conditions (2-8°C) may limit the portability of the test kit.
• The test may not be suitable for diagnosing advanced liver diseases, where other diagnostic methods might be more appropriate.

Use of the Product in the Field

The Hepatic Fibrosis Test YGA1357 // YGA1361 is widely used in clinical laboratories, hepatology clinics, and research settings. It plays a pivotal role in the early diagnosis of liver fibrosis, allowing clinicians to detect and monitor the disease before it progresses to irreversible cirrhosis. The test is typically used in routine liver function screenings, particularly for patients at risk of developing liver disease due to factors such as chronic alcohol use, viral infections, or metabolic conditions. Its ease of use and compatibility with automated analyzers make it an ideal solution for high-volume testing in both clinical and research environments.

Recommendations

To get the best results from the Hepatic Fibrosis Test:

• Ensure proper storage at the recommended temperature of 2-8°C to preserve the accuracy of the reagents.
• Integrate the test into an automated system for faster processing and reduced error rates.
• Use the test regularly for early detection in at-risk populations, improving patient outcomes through timely medical intervention.

Technical Specifications